
|Articles|November 1, 2009
Low-risk prostate cancer well managed with active surveillance
Drs. Scott B. Shappell and Leonard S. Marks discuss clinical use of urine PCA3 mRNA testing for prostate cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5


















